2022, Prague / Barcelona
FutureLife enters Spain and Italy through a strategic partnership with Institut Marquès (‘IM’), one of the most innovative IVF providers in Europe.
Barcelona/Prague, 4 th October 2022 – FutureLife, a leading Pan-European provider of IVF and related genetics services performing in excess of 45,000 IVF cycles annually, backed by Hartenberg Holding (‘Hartenberg’) and CVC Capital Partners (‘CVC’), has announced the acquisition of Institut Marquès, a leading IVF company located in Barcelona.
Institut Marquès, founded over a century ago, is one of the largest fertility clinics in Spain, performing more than 3,000 egg collections per year. The company, headquartered in Barcelona, operates 3 clinics in Spain and 2 clinics in Italy. Institut Marquès, one of the most recognized IVF brands in Europe, is known for its innovation and patient-centric approach, and attracts a global patient base to its state-of-the-art clinics.
Matěj Stejskal, CEO and shareholder of FutureLife: “With the acquisition of Institut Marquès, we continue partnering with the top clinics in Europe focusing on patients and their overall experience during fertility treatment. We are very excited about our partnership with Dr Marisa López-Teijón, one of IVF’s most visionary and influential individuals, and together with her we aim to continue to advance the field of assisted reproduction. Furthermore, we are pleased to support Dr Borja Marquès-Teijón, the new medical director of the company and the fourth generation of the Marquès family in the ongoing development of the company, and participate in their family legacy.”
Dr Marisa López-Teijón, founder and Medical Director of IM: "Partnership with FutureLife will allow us to take our innovative projects and initiatives to a larger scale through the panEuropean network and expertise that FutureLife has developed. Even in our earliest introductions, we knew that the FutureLife was the right partner for our growth plans. We share a common view on our approach to patients and the quality of treatment that we provide to them.”
Dr Borja Marquès López-Teijón, who will lead the medical operations of IM as a medical director and continue as a shareholder of the company: “This partnership gives us an opportunity to benefit from shared knowledge and learnings, best practices, as well as to benefit from other synergies as a member of a large group. We are particularly excited that FutureLife chose Institut Marquès as its entry point to Spain and Italy and we believe we can together expand our footprint across the whole region.”